Spitzer, Martin S <br/><br/>
Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.  [electronic resource] 

 -  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie  Dec 2007 
 - 1837-42 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0721-832X 
<br/><br/><label>Standard No.: </label>10.1007/s00417-007-0568-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--toxicity<br/>Animals<br/>Antibodies, Monoclonal--toxicity<br/>Antibodies, Monoclonal, Humanized<br/>Aptamers, Nucleotide--toxicity<br/>Bevacizumab<br/>Cell Proliferation--drug effects<br/>Cell Survival<br/>Cells, Cultured<br/>Choroid--blood supply<br/>DNA--biosynthesis<br/>Endothelium, Vascular--drug effects<br/>Enzyme-Linked Immunosorbent Assay<br/>Humans<br/>Immunohistochemistry<br/>Materials Testing<br/>Pigment Epithelium of Eye--drug effects<br/>Ranibizumab<br/>Rats<br/>Retinal Ganglion Cells--drug effects<br/>Swine<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor Receptor-1--metabolism<br/>Vascular Endothelial Growth Factor Receptor-2--metabolism<br/>von Willebrand Factor--metabolism